Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 101–200 of 1,001
Havrdová, E., Belova, A., Goloborodko, A., Tisserant, A., Wright, A., Wallstroem, E., Garren, H., Maguire, R. P., & Johns, D. R. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8128-x · Cited by 224
Calcinotto, A., Brevi, A., Chesi, M., Ferrarese, R., Garcia Perez, L., Grioni, M., Kumar, S., Garbitt, V. M., Sharik, M. E., Henderson, K. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07305-8 · Cited by 223
von Stebut, E., Reich, K., Thaçi, D., Koenig, W., Pinter, A., Körber, A., Rassaf, T., Waisman, A., Mani, V., Yates, D., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.042 · Cited by 224
“Safety Overall, safety results were comparable to those of other secukinumab studies (Bissonnette et al., 2018; Langley et al., 2014; van de Kerkhof et al., 2016) (see Supplementary Tables S6 and S7 online).”
BackgroundResultHara-Chikuma, M., Satooka, H., Watanabe, S., Honda, T., Miyachi, Y., Watanabe, T., & Verkman, A. S. (2015) · Nature Communications · doi:10.1038/ncomms8454 · Cited by 217
The Role of Helper T Cells in Psoriasis
Hu, P., Wang, M., Gao, H., Zheng, A., Li, J., Mu, D., & Tong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.788940 · Cited by 214
An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease
Ungar, B., Garcet, S., Gonzalez, J., Dhingra, N., Correa da Rosa, J., Shemer, A., Krueger, J. G., Suarez-Farinas, M., & Guttman-Yassky, E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.037 · Cited by 213
“(i) Unlike in psoriasis (Langley et al., 2014; McInnes et al., 2015), it is difficult to quantify improvements in erythema and lichenification because of lack of demarcation between lesional and nonlesional areas, contributing to very high placebo responses in AD (up to 25%) (Hamilton et al.”
BackgroundInterleukin-12: Functional activities and implications for disease
Zundler, S., & Neurath, M. F. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.003 · Cited by 212
Armstrong, A. W., Blauvelt, A., Callis Duffin, K., Huang, Y.-H., Savage, L. J., Guo, L., & Merola, J. F. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00630-5 · Cited by 200
Liu, L., Kikly, K., Lu, J., Allan, B., Tang, Y., Tetreault, J., Chow, C.-K., Barmettler, B., Nelson, J., Bina, H., et al. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s100940 · Cited by 208
Warren, R. B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., & Paul, C. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19341 · Cited by 211
Mrowietz, U., Leonardi, C. L., Girolomoni, G., Toth, D., Morita, A., Balki, S. A., Szepietowski, J. C., Regnault, P., Thurston, H., & Papavassilis, C. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.04.011 · Cited by 208
Role of the IL23/IL17 Pathway in Crohn’s Disease
Schmitt, H., Neurath, M. F., & Atreya, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622934 · Cited by 206
Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes
Moos, S., Mohebiany, A. N., Waisman, A., & Kurschus, F. C. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.01.006 · Cited by 204
“However, in contrast to psoriasis patients treated with IL-17 pathwayeneutralizing drugs, who often show a complete remission (Langley et al., 2014; Papp et al., 2012; Waisman, 2012), mice deficient for IL-17RA are not fully resistant to disease development but show residual disease scores (El Malki et al.”
ResultReich, K., Papp, K. A., Matheson, R. T., Tu, J. H., Bissonnette, R., Bourcier, M., Gratton, D., Kunynetz, R. A., Poulin, Y., Rosoph, L. A., et al. (2015) · Experimental Dermatology · doi:10.1111/exd.12710 · Cited by 204
Pathophysiology of psoriasis: A review
Yamanaka, K., Yamamoto, O., & Honda, T. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15913 · Cited by 204
Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases
Fragoulis, G. E., Siebert, S., & McInnes, I. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-051914-021944 · Cited by 201
Cytokines IL-17 and IL-22 in the host response to infection
Valeri, M., & Raffatellu, M. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw111 · Cited by 202
“2012; Langley et al.”
BackgroundAn IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis
Paller, A. S., Renert-Yuval, Y., Suprun, M., Esaki, H., Oliva, M., Huynh, T. N., Ungar, B., Kunjravia, N., Friedland, R., Peng, X., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.019 · Cited by 204
“Advances in understanding pathogenesis have translated into rapid development of cytokine-targeted therapeutics, which reverse the clinical inflammation but also the epidermal disease phenotype.(84,86-96) Pathogenesis-based therapies are available for psoriasis based on its TH17/IL-23–centered activation.”
BackgroundCurrent Developments in the Immunology of Psoriasis.
Grän, F., Kerstan, A., Serfling, E., Goebeler, M., & Muhammad, K. (2020) · The Yale Journal of Biology and Medicine · Cited by 307
Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14878 · Cited by 200
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
von Stebut, E., Boehncke, W.-H., Ghoreschi, K., Gori, T., Kaya, Z., Thaci, D., & Schäffler, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03096 · Cited by 199
“treatment in head-to-head double-blind randomized trials was superior to established biological treatments like etanercept (TNF inhibitor) and ustekinumab (anti-IL12/23), raising the bar, where more than 80% of the patients achieved a PASI 90 and DLQI of 0/1 (35, 41, 42).”
BackgroundMethodEtiology and Pathogenesis of Psoriasis
Boehncke, W.-H. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.07.013 · Cited by 197
The translational revolution and use of biologics in patients with inflammatory skin diseases
Noda, S., Krueger, J. G., & Guttman-Yassky, E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.015 · Cited by 198
Saeki, H., Nakagawa, H., Nakajo, K., Ishii, T., Morisaki, Y., Aoki, T., Cameron, G. S., Osuntokun, O. O., & the Japanese Ixekizumab Study Group (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13622 · Cited by 195
Schreiber, S., Colombel, J.-F., Feagan, B. G., Reich, K., Deodhar, A. A., McInnes, I. B., Porter, B., Das Gupta, A., Pricop, L., & Fox, T. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214273 · Cited by 195
Cytokines in inflammatory bowel diseases – Update 2020
Leppkes, M., & Neurath, M. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104835 · Cited by 192
Naik, H. B., Natarajan, B., Stansky, E., Ahlman, M. A., Teague, H., Salahuddin, T., Ng, Q., Joshi, A. A., Krishnamoorthy, P., Dave, J., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306460 · Cited by 193
PASI 90 response: the new standard in therapeutic efficacy for psoriasis
Puig, L. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12817 · Cited by 193
Reich, K., Pinter, A., Lacour, J. P., Ferrandiz, C., Micali, G., French, L. E., Lomaga, M., Dutronc, Y., Henneges, C., Wilhelm, S., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15666 · Cited by 192
Krueger, J. G., Wharton, K. A., Schlitt, T., Suprun, M., Torene, R. I., Jiang, X., Wang, C. Q., Fuentes-Duculan, J., Hartmann, N., Peters, T., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.04.029 · Cited by 188
“org).(25) Because efalizumab, a psoriasis therapy that reduces T-cell activation, was withdrawn from themarket in 2009 because of serious infections such as progressivemultifocal leukoencephalopathy,(32) we tested whether secukinumab affected T-cell activation.”
BackgroundResultInfluentialChen, L., & Tsai, T.-F. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16083 · Cited by 187
Papp, K. A., Merola, J. F., Gottlieb, A. B., Griffiths, C. E. M., Cross, N., Peterson, L., Cioffi, C., & Blauvelt, A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.037 · Cited by 189
Caillon, A., & Schiffrin, E. L. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0628-7 · Cited by 186
IL‐17: overview and role in oral immunity and microbiome
Abusleme, L., & Moutsopoulos, N. (2017) · Oral Diseases · doi:10.1111/odi.12598 · Cited by 183
“Specifically, to date Secukinumab the human IL-17 antagonist has been FDA approved for the treatment of psoriatic arthritis, ankylosing spondylitis and plaque psoriasis (Langley et al., 2014).”
Griffiths, C. E. M., Thaçi, D., Gerdes, S., Arenberger, P., Pulka, G., Kingo, K., Weglowska, J., on behalf of the EGALITY study group, Hattebuhr, N., Poetzl, J., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15152 · Cited by 184
Immunotherapy in myasthenia gravis in the era of biologics
Dalakas, M. C. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0110-z · Cited by 181
Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis
Mashiko, S., Bouguermouh, S., Rubio, M., Baba, N., Bissonnette, R., & Sarfati, M. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.033 · Cited by 180
Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis
Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, A., Costanzo, A., Conti, A., Dapavo, P., De Simone, C., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14114 · Cited by 182
Multilevel Network Meta-Regression for Population-Adjusted Treatment Comparisons
Phillippo, D. M., Dias, S., Ades, A. E., Belger, M., Brnabic, A., Schacht, A., Saure, D., Kadziola, Z., & Welton, N. J. (2020) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/rssa.12579 · Cited by 180
“Information on five clinically relevant covariates that were thought to be potential effect modifiers is available on individuals in the UNCOVER trials, and summary statistics on the same covariates were extracted from the FIXTURE trial (Langley et al., 2014).”
MethodInfluentialNeutrophilic inflammation in the respiratory mucosa predisposes to RSV infection
Habibi, M. S., Thwaites, R. S., Chang, M., Jozwik, A., Paras, A., Kirsebom, F., Varese, A., Owen, A., Cuthbertson, L., James, P., et al. (2020) · Science · doi:10.1126/science.aba9301 · Cited by 180
Sieper, J., Deodhar, A., Marzo-Ortega, H., Aelion, J. A., Blanco, R., Jui-Cheng, T., Andersson, M., Porter, B., & Richards, H. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210023 · Cited by 178
Cytokines in Graft-versus-Host Disease
Henden, A. S., & Hill, G. R. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500117 · Cited by 176
Bai, F., Li, G. G., Liu, Q., Niu, X., Li, R., & Ma, H. (2019) · Journal of Immunology Research · doi:10.1155/2019/2546161 · Cited by 174
“Four studies [15, 16, 23] did not report the reasons for missing data and were given a high risk of bias.”
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
Kim, J., & Krueger, J. G. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103905 · Cited by 174
Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis
Frieder, J., Kivelevitch, D., & Menter, A. (2018) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317738910 · Cited by 177
Targeting cytokines for treatment of neuropathic pain
Hung, A. L., Lim, M., & Doshi, T. L. (2017) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2017.08.002 · Cited by 174
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Doney, L., Dressler, C., Hua, C., Hughes, C., Naldi, L., Afach, S., & Le Cleach, L. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub3 · Cited by 173
Mease, P. J. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000147 · Cited by 171
Uluçkan, Ö., Jimenez, M., Karbach, S., Jeschke, A., Graña, O., Keller, J., Busse, B., Croxford, A. L., Finzel, S., Koenders, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8996 · Cited by 170
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, E., Chaimani, A., Garcia-Doval, I., Doney, L., Dressler, C., Hua, C., Hughes, C., Naldi, L., Afach, S., & Le Cleach, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub4 · Cited by 170
Merola, J. F., Qureshi, A., & Husni, M. E. (2018) · Dermatologic Therapy · doi:10.1111/dth.12589 · Cited by 168
“…development of new therapeutics aimed at IL-17 blockade, and these agents (e.g., secukinumab, ixekizumab) have strong efficacy and good safety in latephase clinical trials for moderate-to-severe plaque psoriasis (Langley et al., 2014; Leonardi et al., 2012; Martin et al., 2013; Papp et al., 2012).”
Backgroundon behalf of the FUTURE 3 study group, Nash, P., Mease, P. J., McInnes, I. B., Rahman, P., Ritchlin, C. T., Blanco, R., Dokoupilova, E., Andersson, M., Kajekar, R., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1551-x · Cited by 165
“1 patient-years of exposure to any secukinumab dose and showed no new or unexpected safety signals, and was consistent with earlier reports of secukinumab in PsA [16] and psoriasis [13].”
ResultCytokines and costimulation in acute graft-versus-host disease
Hill, G. R., & Koyama, M. (2020) · Blood · doi:10.1182/blood.2019000952 · Cited by 164
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Nogueira, M., Puig, L., & Torres, T. (2020) · Drugs · doi:10.1007/s40265-020-01261-8 · Cited by 162
Roy, T., Boateng, S. T., Uddin, M. B., Banang-Mbeumi, S., Yadav, R. K., Bock, C. R., Folahan, J. T., Siwe-Noundou, X., Walker, A. L., King, J. A., et al. (2023) · Cells · doi:10.3390/cells12121671 · Cited by 161
PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment
Cugno, M., Borghi, A., & Marzano, A. V. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0265-1 · Cited by 162
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Hohenberger, M., Cardwell, L. A., Oussedik, E., & Feldman, S. R. (2018) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1329511 · Cited by 165
Candida albicans–epithelial interactions and induction of mucosal innate immunity
Naglik, J. R., König, A., Hube, B., & Gaffen, S. L. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.10.030 · Cited by 163
Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
Coates, L. C., FitzGerald, O., Helliwell, P. S., & Paul, C. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.05.012 · Cited by 161
“The first anti-IL-17 antibody, secukinumab [115], has been”
BackgroundSawyer, L. M., Malottki, K., Sabry-Grant, C., Yasmeen, N., Wright, E., Sohrt, A., Borg, E., & Warren, R. B. (2019) · PLOS ONE · doi:10.1371/journal.pone.0220868 · Cited by 161
A Comprehensive Review of Neutrophilic Diseases
Marzano, A. V., Borghi, A., Wallach, D., & Cugno, M. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8621-8 · Cited by 163
Gottlieb, A., Sullivan, J., van Doorn, M., Kubanov, A., You, R., Parneix, A., Hugot, S., & Milutinovic, M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.058 · Cited by 159
“Results from phase 3 clinical trials have demonstrated high efficacy of secukinumab in moderate-to-severe psoriasis, starting at early time points, with a sustained effect and a favorable safety profile.(18-22) Secukinumab has also shown superiority to etanercept(20) and ustekinumab(23) in head-to-head trials.”
BackgroundNovel therapeutic targets in rheumatoid arthritis
Koenders, M. I., & van den Berg, W. B. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.001 · Cited by 159
Patil, R. S., Shah, S. U., Shrikhande, S. V., Goel, M., Dikshit, R. P., & Chiplunkar, S. V. (2016) · International Journal of Cancer · doi:10.1002/ijc.30134 · Cited by 159
“Recently, Secukinumab, monoclonal antibody that binds to human IL17A has been approved for treatment of psoriasis.(46) Other approaches to target IL17 inflammatory axis including monoclonal antibody targeting IL17 receptor (brodalumab), IL23 p40 subunit (ustekinumab), IL23 p19 subunit and small molecules with inverse…”
BackgroundIL-17 in the immunopathogenesis of spondyloarthritis
Taams, L. S., Steel, K. J. A., Srenathan, U., Burns, L. A., & Kirkham, B. W. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0044-2 · Cited by 158
IL-25 (IL-17E) in epithelial immunology and pathophysiology
Borowczyk, J., Shutova, M., Brembilla, N. C., & Boehncke, W.-H. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.12.628 · Cited by 158
Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics
Petit, R. G., Cano, A. C., Ortiz, A., Espina, M., Prat, J., Muñoz-Mateu, M., Severino, P. B., Souto, E. B., García, M. L., Pujol, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094983 · Cited by 195
IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa
Fletcher, J. M., Moran, B., Petrasca, A., & Smith, C. M. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13449 · Cited by 154
Sewell, G. W., & Kaser, A. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac034 · Cited by 176
Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon
Mylonas, A., & Conrad, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02746 · Cited by 172
“While antibodies targeting IL-17 have shown great efficacy in psoriasis (53, 70), blockade of IL-22 failed to meet primary end points in clinical trials indicating distinct role for IL-17 and IL-22 in psoriasis.”
BackgroundAlwan, W., & Nestle, F. O. (2015) · PubMed · Cited by 197
McInnes, I. B., Mease, P. J., Ritchlin, C. T., Rahman, P., Gottlieb, A. B., Kirkham, B. W., Kajekar, R., Delicha, E.-M., Pricop, L., & Mpofu, S. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex301 · Cited by 148
Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study
Mrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R., & Chaouche‐Teyara, K. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.01.066 · Cited by 148
Role of IL-17 in asthma pathogenesis and its implications for the clinic
Ramakrishnan, R. K., Heialy, S. A., & Hamid, Q. A. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1666002 · Cited by 154
Translating nucleic acid-sensing pathways into therapies
Junt, T., & Barchet, W. (2015) · Nature reviews. Immunology · doi:10.1038/nri3875 · Cited by 166
“As recent clinical data establish that psoriasis is a strongly IL-17-dependent disease 99 , this result indicates that dual antagonists of TLR7 and TLR9 modify a disease-relevant pathway.”
Targeting CD8+ T cells prevents psoriasis development
Di Meglio, P., Villanova, F., Navarini, A. A., Mylonas, A., Tosi, I., Nestle, F. O., & Conrad, C. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.046 · Cited by 145
The role of IL-17 in vitiligo: A review
Singh, R. K., Lee, K. M., Vujkovic-Cvijin, I., Ucmak, D., Farahnik, B., Abrouk, M., Nakamura, M., Zhu, T. H., Bhutani, T., Wei, M., et al. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.004 · Cited by 145
Varshney, P., & Saini, N. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.003 · Cited by 156
Papp, K. A., Weinberg, M. A., Morris, A., & Reich, K. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00440-2 · Cited by 164
Campa, M., Mansouri, B., Warren, R., & Menter, A. (2016) · Dermatology and Therapy · doi:10.1007/s13555-015-0092-3 · Cited by 144
“The most common side effects associated with this drug are nasopharyngitis, headache, and upper respiratory infections, which are similar to other biologic drugs [46].”
InfluentialSystemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, É., Chaimani, A., García-Doval, I., Doney, L., Dressler, C., Hua, C., Hughes, C., Naldi, L., Afach, S., & Cleach, L. L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub5 · Cited by 228
Rungapiromnan, W., Yiu, Z. Z. N., Warren, R. B., Griffiths, C. E. M., & Ashcroft, D. M. (2017) · British Journal of Dermatology · doi:10.1111/bjd.14964 · Cited by 156
Smolen, J. S., Agarwal, S. K., Ilivanova, E. P., Xu, X. L., Ye, M., Zhuang, Y., Nnane, I. P., Radziszewski, W., Greenspan, A. J., Beutler, A. M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209831 · Cited by 157
Warren, R. B., Mrowietz, U., von Kiedrowski, R., Niesmann, J., Wilsmann‐Theis, D., Ghoreschi, K., Zschocke, I., Falk, T. M., Blödorn‐Schlicht, N., & Reich, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32127-4 · Cited by 139
Clinical management of psoriatic arthritis
Van den Bosch, F., & Coates, L. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30949-8 · Cited by 139
Kaufman, B. P., & Alexis, A. F. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0332-7 · Cited by 164
Jain, A., Doppalapudi, S., Domb, A. J., & Khan, W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.004 · Cited by 142
“Among these agents, Secukinumab [78] and ixekizumab [79] selectively bind to IL-17A, whereas brodalumab inhibits the IL-17RA subunit [80].”
BackgroundNast, A., Spuls, P. I., van der Kraaij, G. E., Gisondi, P., Paul, C. F., Ormerod, A. D., Saïag, P., Smith, C. H., Daudén, E., de Jong, E. M. G. J., et al. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14454 · Cited by 164
Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes
Cao, P.-P., Wang, Z.-C., Schleimer, R. P., & Liu, Z. (2018) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2018.10.014 · Cited by 156
Mehta, H., Mashiko, S., Angsana, J., Rubio, M., Hsieh, Y.-C. M., Maari, C., Reich, K., Blauvelt, A., Bissonnette, R., Muñoz-Elías, E. J., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.01.005 · Cited by 134
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Sbidian, É., Chaimani, A., Guelimi, R., García-Doval, I., Hua, C., Hughes, C., Naldi, L., Kinberger, M., Afach, S., & Cleach, L. L. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011535.pub6 · Cited by 207
Safety of biologics in psoriasis
Kamata, M., & Tada, Y. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14096 · Cited by 133
Nast, A., Jacobs, A., Rosumeck, S., & Werner, R. N. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.206 · Cited by 143
“, 2010), etanercept (Gottlieb et al., 2003; Leonardi et al., 2003; Krueger et al., 2005; Papp et al., 2005; Tyring et al., 2006,2007; van de Kerkhof et al., 2008; Bagel et al., 2012; Langley et al., 2014), and apremilast (Papp et al.”
BackgroundInfluentialAnti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
Tsai, Y., & Tsai, T. (2017) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x17735756 · Cited by 142
Immunology of IL-12: An update on functional activities and implications for disease
Ullrich, K. A.-M., Schulze, L. L., Paap, E.-M., Müller, T. M., Neurath, M. F., & Zundler, S. (2020) · EXCLI journal · doi:10.17179/excli2020-3104 · Cited by 216
Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies
Bugaut, H., & Aractingi, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.621956 · Cited by 151
“In addition to genetic association studies, the efficacy of monoclonal antibodies targeting IL17 is a strong argument for the implication of this cytokine (35, 36).”
BackgroundAraujo, E. G., Englbrecht, M., Hoepken, S., Finzel, S., Kampylafka, E. I., Kleyer, A., Bayat, S., Schönau, V., Hueber, A. J., Rech, J., et al. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.05.011 · Cited by 130
The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment
ten Bergen, L. L., Petrovic, A., Aarebrot, A. K., & Appel, S. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12946 · Cited by 147
Wu, J. J., Penfold, R. B., Primatesta, P., Fox, T., Stewart, C. C., Reddy, S. P., Egeberg, A., Liu, J., & Simon, G. E. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14175 · Cited by 137
Strober, B. E., Leonardi, C. L., Papp, K. A., Mrowietz, U., Ohtsuki, M., Bissonnette, R., Ferris, L. K., Paul, C. F., Lebwohl, M., Braun, D. K., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.09.026 · Cited by 132
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.